Business
A growing number of psychedelic companies are launching programs to give back to the indigenous tribes whose traditional uses of psychedelics have been critical in shaping contemporary approaches to these medicines.
Therapies are being developed for conditions ranging from Treatment Resistant Depression to strokes to addiction.
Parallels between business and regulation strategies in the two sectors point to examples of what psychedelics companies should and should not do.
A new wave of companies are assisting counselors with medicine, records, music and training.
Miraculix’s kit, the first to offer quantitative rapid results within 10 to 30 minutes, is a significant innovation considering many of the substances people desire to test are illegal.
Cybin and Greenbrook announce partnership to roll out clinic expansion and development of psychedelic therapies.
The DEA approved shipment is a milestone toward legal access to psilocybin mushrooms for U.S. clinical research and health treatments.
Some leading developers of psychedelic medicines are focusing on both plant-derived and synthetic molecules to create unique therapies.
Lindsay Hoover of the JLS Fund examines the market strategies of five publicly traded companies favored by investors to bring psychedelic-assisted therapy to the mainstream.
Cryptocurrencies such as Bitcoin have funded psychedelic research and may pave the way for financial systems that replicate more decentralized psychedelic business structures.
